The FDA Diagnostic Forecast Has a Prior Conviction Problem — And We're Resolving It

Let's start with the IDx-DR problem directly. The 2018 De Novo authorization granted autonomous screening authority — no mandatory physician sign-off required for a positive or negative finding. If our forecast target was simply 'FDA approves first fully AI-driven diagnostic tool,' IDx-DR resolved that YES nearly eight years ago and we've been publishing a zombie probability ever since. That's worse than being wrong — it means we knew about the tension and kept the number live anyway.

So we're doing something we should have done earlier: formally retiring the original forecast target and replacing it with a definition that has a genuine resolution frontier. The new target is: 'FDA authorizes an autonomous AI diagnostic system operating across multiple high-acuity clinical specialties without mandatory physician review in any arm of its deployment.' This is meaningfully different from IDx-DR for three reasons. First, IDx-DR is a narrow screening tool for a single condition (diabetic retinopathy) in a population-level screening context — not interpretation-heavy diagnostic reasoning. Second, the De Novo pathway used for IDx-DR has not been replicated for higher-acuity diagnostic domains; FDA's post-2018 AI guidance has consistently reasserted human-in-the-loop as the assumed architecture. Third, and critically: the AMA's documented lobbying against physician oversight removal intensified after 2018, not before. IDx-DR did not breach the AMA bottleneck — it appears to have hardened it. The AMA accepted the narrow population-screening exception while explicitly opposing extension to interpretation-heavy specialties. That's the tension the original framing left unresolved.

With the redefined target, what does today's evidence actually tell us? CliniComp's 510(k) clearance is the closest analog in today's news cycle — but it's AI-driven decision support within a physician-reviewed workflow. That's not direct evidence toward our forecast; it's proximate evidence that the FDA continues to clear AI-integrated diagnostic infrastructure at volume. The category of FDA action that would constitute direct evidence is narrower: a De Novo or PMA authorization that explicitly removes mandatory physician review requirements in a multi-specialty or high-acuity diagnostic context. We haven't seen that. Pakistan's 1,110-hospital deployment and CellCarta's digital pathology consortium are circumstantial — they confirm international deployment appetite and industry standardization efforts, which are conditions for the forecast, not proof of it. Roche's 3,500 Blackwell GPU commitment tells us diagnostic AI is getting serious infrastructure investment, but GPU count doesn't move a regulatory authorization probability.

Under the redefined target, we're setting the probability at 34% for resolution by December 31, 2027. Here's what drives that number: the FDA is in an expansion posture institutionally — 500+ cleared devices, adaptive framework signals, cost-pressure from healthcare systems that are increasingly vocal. That's the upside case. But the AMA's structural resistance to removing physician oversight in interpretation-heavy domains, the absence of any liability framework for fully autonomous high-acuity diagnostics, and the FDA's own stated architecture assumptions all weigh against resolution in the near term. The 34% reflects genuine momentum against a genuine wall — not a coin flip. What would move us above 50%: a formal FDA guidance document explicitly contemplating autonomous authorization pathways for AI diagnostics outside the narrow screening category, or a stated AMA position revision. What would drop us below 20%: a high-profile autonomous diagnostic error in any jurisdiction generating congressional or professional body blowback that triggers FDA retrenchment. We're watching both.